Anti-CD123 chimeric antigen receptor redirected T cells for relapsed B-cell acute lymphoblastic leukemia

Abstract

patients before or immediately after mCTL infusion. In the absence of conventional therapy, 8 of the 11 patients with CMV infection became negative for CMV in the blood within 7d of mCTL infusion, with a coinciding rise in CMV-specific CTL in PB. Each of 8 patients with high EBV loads cleared their virus, as did 7 of 7 patients with adenoviral infections/disease. Overall the response rate in both groups was 88%. This study demonstrates that mCTL derived from the PB of seropositive donors as well as the CB of virus naive donors expand in vivo and are active against multiple viruses. Furthermore, by restoring immunity to multiple viruses simultaneously, the need for continued prophylaxis with pharmacotherapy is eliminated, thus, improving the efficiency and cost effectiveness of protecting SCT and CBT recipients from these potentially lethal viruses.